WOBE437
| Clinical data | |
|---|---|
| Other names | WOBE-437 |
| Drug class | Selective endocannabinoid reuptake inhibitor (SERI) |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H33NO3 |
| Molar mass | 359.510 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research.[1][2]
It is a highly potent and selective endocannabinoid reuptake inhibitor, with an IC50 of 10 nM in terms of this action.[1][2][3] The drug produces anxiolytic-like, anti-inflammatory, analgesic, antiallodynic, and muscle relaxant effects in rodents.[1][2][4] These effects are mediated by increased endocannabinoid levels, including of anandamide (AEA) and 2-arachidonylglycerol (2-AG), and are dependent on cannabinoid receptors, for instance the cannabinoid CB1 receptor.[1][2] Conversely, WOBE437 did not produce catalepsy, affect locomotor activity, or produce the typical sedation of cannabinoid CB1 receptor agonists.[2][4] The drug also showed effectiveness in an animal model of multiple sclerosis.[4] Originally believed to be selective, off-target activities of WOBE437 have subsequently been identified and described.[5]
WOBE437 is orally bioavailable in rodents.[2]
Numerous analogues of WOBE437 have been explored in search of candidates with better drug-like properties, though a series of almost 80 compounds found none that were more potent than WOBE437 itself.[3]
WOBE437 was first described in the scientific literature by 2013.[6][1]
See also
References
- ^ a b c d e Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, Petrucci V, et al. (June 2017). "Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake". Proceedings of the National Academy of Sciences of the United States of America. 114 (25): E5006–E5015. Bibcode:2017PNAS..114E5006C. doi:10.1073/pnas.1704065114. PMC 5488949. PMID 28584105.
- ^ a b c d e f Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J (2018). "The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors". Frontiers in Molecular Neuroscience. 11 180. doi:10.3389/fnmol.2018.00180. PMC 5992379. PMID 29910713.
- ^ a b Mäder P, Bartholomäus R, Nicolussi S, Baumann A, Weis M, Chicca A, et al. (January 2021). "Synthesis and Biological Evaluation of Endocannabinoid Uptake Inhibitors Derived from WOBE437". ChemMedChem. 16 (1): 145–154. doi:10.1002/cmdc.202000153. PMID 32369259.
- ^ a b c Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, Chicca A (April 2021). "Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis". ACS Pharmacology & Translational Science. 4 (2): 765–779. doi:10.1021/acsptsci.0c00214. PMC 8033750. PMID 33860200.
- ^ Gagestein B, Stevens AF, Fazio D, Florea BI, van der Wel T, Bakker AT, et al. (May 2022). "Chemical Proteomics Reveals Off-Targets of the Anandamide Reuptake Inhibitor WOBE437". ACS Chemical Biology. 17 (5): 1174–1183. doi:10.1021/acschembio.2c00122. PMC 9127799. PMID 35482948.
- ^ Nicolussi S, Chicca A, Soeberdt M, Abels C, Gertsch J (18 April 2013). Prototype of a novel class of potent, selective endocannabinoid reuptake inhibitors. 6th European Workshop on Cannabinoid Research. Dublin, Ireland: Trinity College Dublin. Retrieved 27 May 2026 – via ResearchGate.